• Asian Pacific Journal of Cancer Prevention
• /
• 제14권7호
• /
• pp.4061-4066
• /
• 2013

The extranodal natural killer/T-cell lymphoma (ENKTL) shows high local or systemic failure rates when radiotherapy (RT) is taken as the primary treatment, suggesting a role for chemotherapy (CT) added to RT for this disease. However, the appropriate mode of combined modality therapy (CMT) has not been fully defined. A total of one hundred and twenty-one patients with ENKTL receiving sandwich CT with RT were reviewed between January 2003 and August 2012. The primary endpoints were the response rate, progression-free survival (PFS), overall survival (OS), and the relapse rate. After the initial CT, there were 84 (69.4%) patients in CR, 22 (18.2%) patients in PR, 9 (7.4%) patients in SD, and 6 (5%) patients in PD, respectively. At the end of RT, the CR, PR, SD, and PD rates for all patients were 90.9% (n=110), 1.7% (n=2), 4.1% (n=5), and 3.3% (n=4), respectively. After a median follow-up of 42.3 months (3.5~112.3 months), the 5-year PFS was 74.7% (95% CI 70.4%~79.0%), and 5-year OS was 77.3% (95% CI 67.9%~86.7%). Disease progression was documented in 25 (20.7%) patients. The rates of systemic failure, local failure, and regional failure were 18.2%, 5.8%, 1.7%, respectively. Twenty death events (16.5%) were observed for the entire group of patients (18 deaths related to PD). Furthermore, CR to the initial CT and low Korean Prognostic Index (KPI) can independently predict long PFS and OS. The sandwich CMT achieved an excellent outcome for localized ENKTL with acceptable toxicity. We recommend it can be applied as the optimal choice for localized ENKTL.

• Radiation Oncology Journal
• /
• 제20권1호
• /
• pp.17-23
• /
• 2002

목적 : 국한성 두경부 혈관 중심위 림프종에서 화학방사선 병용치료법과 방사선치료 단독요법의 치료성적을 비교하여 화학방사선 병용치료법의 임상적 유용성 여부를 알아보고자 하였다. 대상 및 방법 : 1976년부터 1995년까지 연세암센타에서 병기 I, II기의 두경부 혈관 중심위 림프종으로 치료받은 143 예를 대상으로 하였다. 방사선치료단독(104예)의 경우 20~70 Gy (중앙값 50.4 Gy)를 병소 부위에 국소적으로 조사하였고 화학방사선 병용치료(39예)의 경우에는 1~6회(중앙값 3회)의 화학요법을 시행한 후 병소 부위에 국소적으로 방사선치료를 시행하였다. 치료방법에 따른 반응율, 치료실패양상, 후유증, 생존율 등을 비교하여 보았다. 결과 : 치료에 대한 높은 반응율에도 불구하고 국소치료실패가 치료실패양상의 가장 흔한 원인이었고 화학요법의 시행에 따른 치료실패양상의 변화는 없었다. 치료방법에 따른 환자들의 순응도에는 차이가 없었으나 혈구포식세포 증후군(hemophagocytic syndrome), 패혈증, 난치성 출혈(intractable bleeding), 2차 암(new primary cancer) 등의 발생 빈도는 화학방사선 병용치료법을 시행한 경우에 방사선치료 단독요법을 시행한 경우보다 높은 경향을 나타냈다. 방사선 단독으로 치료한 경우의 5년 생존율과 무병 생존율은 각각 38%와 32%로 저조하였고 화학요법의 시행에도 생존율의 향상은 없었다. 완전관해 여부가 단변량과 다변량 분석에서 가장 중요한 예후인자이었고 화학요법의 병용 여부는 생존율에 영향을 미치지 못했다. 결론 : 국한성 두경부 혈관 중심위 림프종의 치료에서 화학방사선 병용치료법이 방사선치료 단독요법보다 유용하다는 사실이 입증되지 못하였다.

• Asian-Australasian Journal of Animal Sciences
• /
• 제15권5호
• /
• pp.751-756
• /
• 2002

A study was carried out to evaluate the incidences and causes of bovine mastitis in Tanzanian shorthorn zebu (Bos indicus) in the traditional sector and crossbred cows (Bos taurus${\times}$Bos indicus) in the dairy ranching sector, both found under the extensive range management system. Management practices were evaluated through a survey study using structured questionnaires. A total of 120 lactating cows (60 cows from each sector) were screened for the disease using the California Mastitis Test (CMT). Confirmatory tests used for infected cows included; the Direct Microscopic Somatic Cell Count (DMSCC), culture, bacteriological and biochemical laboratory assays. Survey results showed that management practices were generally very poor in both sectors with 84% of the surveyed herds being kept and milked under very unhygienic environmental conditions. The level of infection was higher in the crossbred cows (5% clinical and 38.3% sub-clinical mastitis) and lower in the zebu cows with only sub-clinical mastitis (23.3%). Crossbred cows had (p<0.05) higher somatic cell counts than zebu cows. The four highest-ranking bacterial isolates in order of importance were Staphylococcus aureus, Escherichia coli, Streptococcus agalactiae and Bacillus spp. It was concluded that bovine mastitis under the extensive management system in Tanzania was a result of poor management practices and that zebu cows were more resistant to the diseases than crossbred cows.

• BMB Reports
• /
• 제41권12호
• /
• pp.868-874
• /
• 2008

Neurofilaments (NFs) are neuronal intermediate filaments composed of light (NF-L), middle (NF-M), and heavy (NF-H) subunits. NF-L self-assembles into a "core" filament with which NF-M or NF-H co-assembles to form the neuronal intermediate filament. Recent reports show that point mutations of the NF-L gene result in Charcot-Marie-Tooth disease (CMT). However, the most recently described rod domain mutant of human NF-L (A148V) has not been characterized in cellular level. We cloned human NF-L and used it to engineer the A148V. In phenotypic analysis using SW13 cells, A148V mutation completely abolished filament formation despite of presence of NF-M. Moreover, A148V mutation reduced the levels of in vitro self-assembly using GST-NF-L (H/R) fusion protein whereas control (A296T) mutant did not affect the filament formation. These results suggest that alanine at position 148 is essentially required for NF-L self-assembly leading to subsequent filament formation in neuronal cells.

• 대한한의학회지
• /
• 제40권1호
• /
• pp.86-98
• /
• 2019

Objectives: This study analyzes the electronic medical record (EMR) data of the spine specialist oriental hospital and clinic in various regions, and reports the actual number and used cases of Chuna therapy. Methods: 2,470,772 data was extracted retrospectively from electronic medical records of all inpatients and outpatients who were treated chuna therapy at 21 Korean medicine hospitals and clinics from January 1, 2018 to December 31, 2018. The characteristics of medical treatment using chuna therapy reflect the minimum, maximum and average values of the number of hospitalized patients, length of hospitalization, frequency of hospitalization, number of outpatients, frequency of treatment and frequency of visit. Diseases were classified in the proportion of Chuna treatment according to the KCD, 7th edition. The chuna and blindness charts were derived accordingly from illness and disease of each part of the body. Results: During the study period, a total 1,342,022 inpatients and outpatients visited the study sites. The male proportion was a little higher than the females' (male: 53.7%, female: 46.3%). According to age, the 30s and 40s were more than half the total(30s: 33.0% and 40s: 20.1%). Chuna therapy was treated to more outpatients than hospitalized patients (outpatient: 83.6%, hospitalization: 16.4%), and most treatments were related to musculoskeletal illness(99.06%). Conclusions: As a result of this study, 1,342,389 chuna therapy was performed in 21 hospitals for one year. As highly demanded by the public, we look forward to ensuring national health care options and medical access when health insurance for chuna therapy is applied beginning March 2019.